Bafna Pharma Stock Price Analysis and Quick Research Report. Is Bafna Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Bafna Pharma. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Bafna Pharma has a PE ratio of 45.3150935836529 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Bafna Pharma has ROA of 2.7613% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Bafna Pharma has a Current ratio of 1.634.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Bafna Pharma has a ROE of 5.0137%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Bafna Pharma has a Debt to Equity ratio of 0.3325 which means that the company has low proportion of debt in its capital.

• Sales growth: Bafna Pharma has reported revenue growth of -4.3345% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Bafna Pharma for the current financial year is 7.45661846877421%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Bafna Pharma is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Bafna Pharma is Rs 3.4942. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Bafna Pharma in Ticker for free. Also, one can get the intrinsic value of Bafna Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Bafna Pharma FAQs

Q1. What is Bafna Pharma share price today?
Ans: The current share price of Bafna Pharma is Rs 158.34.

Q2. What is the market capitalisation of Bafna Pharma?
Ans: Bafna Pharma has a market capitalisation of Rs 374.57440839 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Bafna Pharma?
Ans: The PE ratio of Bafna Pharma is 45.3150935836529 and the P/B ratio of Bafna Pharma is 4.24704418170504, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Bafna Pharma share?
Ans: The 52-week high share price of Bafna Pharma is Rs 176.33, and the 52-week low share price of Bafna Pharma is Rs 69.

Q5. Does Bafna Pharma pay dividends?
Ans: Currently, Bafna Pharma does not pay dividends. Dividend yield of Bafna Pharma is around 0%.

Q6. What are the face value and book value of Bafna Pharma shares?
Ans: The face value of Bafna Pharma shares is Rs 10, while the book value per share of Bafna Pharma is around Rs 37.2824. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Bafna Pharma?
Ans: Bafna Pharma has a total debt of Rs 28.1986 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Bafna Pharma?
Ans: The ROE of Bafna Pharma is 5.0137% and ROCE of Bafna Pharma is 6.3087%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Bafna Pharma a good buy for the long term?
Ans: The Bafna Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Bafna Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Bafna Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Bafna Pharma’s financials?
Ans: You can review Bafna Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.